Diabetes Hypertension Preserved Ejection Fraction 
Circulation
OCTOBER 13, 2023
BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Nonresistant hypertension was defined as BP above threshold but not meeting aTRH criteria. Rates of the primary outcome were 8.7
European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF).
DAIC
FEBRUARY 29, 2024
ET Main Tent (Hall B1) Effect of Gamification, Financial Incentives or Both Combined to Increase Physical Activity Among Patients with Elevated Risk For Major Adverse Cardiovascular Events. 12:15 p.m.
Cardiometabolic Health Congress
JULY 25, 2023
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] I think we live in a very exciting time right now for those who work in diabetes and cardiovascular disease.
European Journal of Heart Failure
FEBRUARY 4, 2024
Phenomics analyses identified unique druggable inflammatory markers in HFpEF from the tumour necrosis factor receptor superfamily (TNFRSF), which were positively associated with hypertension, diabetes, and increased posterior and relative wall thickness.
DAIC
JUNE 26, 2024
Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.
Expert insights. Personalized for you.
40 
Let's personalize your content